Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
Headlines
2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care
2025.11.06
Professors Michael R. Bishop and Edmund K. Waller Visit Peking University Institute of Hematology:Sino–U.S. Experts Discuss the Future of Cell Therapy
2025.11.06
Prof. Kun Wang: A 72-Hour Pegfilgrastim Dosing Strategy Significantly Reduces Bone Pain and Optimizes Supportive Care in Breast Cancer
2025.11.05
ESMO China Voice | Prof. Guiying Xu: High Concordance of PIK3CA Mutations Between Primary and Metastatic Lesions in HR+/HER2– Breast Cancer
2025.11.05
ESMO China Voice | Prof. Min Yan: First Data from the JS105 Study Announced — Promising Potential in PIK3CA-Mutant Populations
2025.11.05
ESMO China Voice | Prof. Jiayu Wang: MAIC Analysis Highlights the Potential of Bireociclib as a Second-Line Therapy for HR+/HER2– Advanced Breast Cancer, Offering a New Treatment Option for Patients 
2025.11.05
Prof. Man Li’s Team Reveals CDK12–ERBB2 Co-Amplification Mechanism and Explores a Novel “Metabolism–Repair–Resistance” Pathway
2025.11.05
ESMO Hot Topic | Professor Zhao Yanxia: PATINA Trial PRO Data Confirm Palbociclib Combination Extends PFS Without Compromising Quality of Life
2025.11.05
ESMO Hot Topic | Professor Zhang Juliang: Long-Term GeparNuevo Follow-Up Reveals Durable Survival Benefits from Durvalumab Neoadjuvant Therapy in Early Triple-Negative Breast Cancer 
2025.11.05
ESMO Hot Topic | Professor Li Huiping: monarchE Trial OS Results Announced — A New Breakthrough in Adjuvant Therapy for HR+/HER2- High-Risk Early Breast Cancer 
2025.11.05
Posted inIOncology

2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care

Posted by By Peter W. PENG 2025.11.06
Continue Reading
Posted inHematology Frontier

Professors Michael R. Bishop and Edmund K. Waller Visit Peking University Institute of Hematology:Sino–U.S. Experts Discuss the Future of Cell Therapy

Posted by By Mourabit Halima 2025.11.06
Continue Reading
SUNMO Study: Mosunetuzumab + Polatuzumab Shows Breakthrough in DLBCL Treatment丨Professor Jason Weston

SUNMO Study: Mosunetuzumab + Polatuzumab Shows Breakthrough in DLBCL Treatment丨Professor Jason Weston

Posted by By Mourabit Halima 2025.09.04
Editor's Note: In 2025, the International Conference on Malignant Lymphoma (ICML) brought together top global hematologic oncology experts to discuss the latest advancements and future trends in lymphoma treatment. During…
Read More
POLARIX Trial: Pola-R-CHP Shows Clear Benefit in Specific DLBCL Subtypes丨Dr. Eleonora Calabretta on the Role of DLBclass

POLARIX Trial: Pola-R-CHP Shows Clear Benefit in Specific DLBCL Subtypes丨Dr. Eleonora Calabretta on the Role of DLBclass

Posted by By Peng Longmei 2025.09.04
Editor's Note: At a highly anticipated hematologic oncology conference, the Late-Breaking Abstract (LBA) session became a focal point. Co-chaired by Professor Kim Linton from the University of Manchester and Professor…
Read More
AZD0486 (Suvatomib) Shows Strong Efficacy and Safety in Relapsed/Refractory DLBCL丨Professor Maruyama on Latest Clinical Insights

AZD0486 (Suvatomib) Shows Strong Efficacy and Safety in Relapsed/Refractory DLBCL丨Professor Maruyama on Latest Clinical Insights

Posted by By Peng Geng 2025.09.04
Editor's Note: The global oncology community continues to focus on cutting-edge breakthroughs in lymphoma treatment. At an important academic conference, Professor Maruyama from Keio University Hospital in Tokyo, Japan, presented…
Read More
CLL Breakthrough: BTK Degrader Bexobrutideg Shows Rapid, Durable Responses丨Professor Alexey Danilov on NX-5948

CLL Breakthrough: BTK Degrader Bexobrutideg Shows Rapid, Durable Responses丨Professor Alexey Danilov on NX-5948

Posted by By Mourabit Halima 2025.09.04
Editor's Note: At this conference, Professor Alexey Danilov (Professor of Hematology, Associate Director of the Lymphoma Center, and Director of the Early Therapeutics Program at City of Hope National Medical…
Read More
EO2463 Peptide Immunotherapy Shows Promise in Follicular and Marginal Zone Lymphoma丨18-ICML

EO2463 Peptide Immunotherapy Shows Promise in Follicular and Marginal Zone Lymphoma丨18-ICML

Posted by By Peter W. PENG 2025.09.04
Editor's Note: At ICML conference, Professor Jose C. Villa Boas from Rochester, USA, was invited to present an oral report titled "EO2463 Peptide Immunotherapy in Combination with Lenalidomide and Rituximab…
Read More
New Era in Non-Hodgkin Lymphoma: Professor Franck Morschhauser on Breakthrough Phase I Results of a Novel BCL6 Degrader

New Era in Non-Hodgkin Lymphoma: Professor Franck Morschhauser on Breakthrough Phase I Results of a Novel BCL6 Degrader

Posted by By Mourabit Halima 2025.09.04
Editor's Note: The conference brought together top experts in lymphoma research from home and abroad, engaging in in-depth discussions on cutting-edge topics such as novel molecular targeted therapies and cell…
Read More
Extranodal Lymphoma Treatment Enters a New Era: IELSG’s 30-Year Journey of Academic Breakthroughs and Future Prospects丨Memorial Lecture

Extranodal Lymphoma Treatment Enters a New Era: IELSG’s 30-Year Journey of Academic Breakthroughs and Future Prospects丨Memorial Lecture

Posted by By Mourabit Halima 2025.09.03
Editor's Note: The 18th International Conference on Malignant Lymphoma (ICML) was held, gathering top experts in the lymphoma field in Lugano. At the prestigious John Ultmann Memorial Lecture, Professor Emanuele…
Read More
A New Era in Molecular Subtyping of Aggressive B-cell Lymphoma: Professor David W. Scott on Genomics-Guided Precision Therapy丨EHA 2025

A New Era in Molecular Subtyping of Aggressive B-cell Lymphoma: Professor David W. Scott on Genomics-Guided Precision Therapy丨EHA 2025

Posted by By Ren Jiamo 2025.09.03
Editor's Note: In 2025, the International Conference on Malignant Lymphoma (ICML) convened in Switzerland, bringing together the world's leading experts in the field of lymphoma. At the conference, Professor David…
Read More
The Journey of Disease Discovery: Professor Elaine Jaffe Reviews a Century of Lymphoma Diagnosis and Classification

The Journey of Disease Discovery: Professor Elaine Jaffe Reviews a Century of Lymphoma Diagnosis and Classification

Posted by By Peng Longmei 2025.09.03
Editor's Note: The International Hematologic Oncology Pathology Conference brought together top experts in hematopathology research from home and abroad for in-depth discussions on cutting-edge topics such as lymphoma diagnosis, classification…
Read More

Professor Bruce D. Cheson on Breakthroughs in Lymphoma Treatment: Innovation Pathways and Future Vision丨EHA 2025

Posted by By Mourabit Halima 2025.09.03
Editor's Note: The conference focused on the latest diagnostic and therapeutic advances in lymphoid system tumors, providing a cutting-edge academic exchange platform for the global oncology community. At this prestigious…
Read More

Posts pagination

Previous page 1 … 13 14 15 16 17 … 20 Next page
Recent Posts
  • 2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care
  • Professors Michael R. Bishop and Edmund K. Waller Visit Peking University Institute of Hematology:Sino–U.S. Experts Discuss the Future of Cell Therapy
  • Prof. Kun Wang: A 72-Hour Pegfilgrastim Dosing Strategy Significantly Reduces Bone Pain and Optimizes Supportive Care in Breast Cancer
  • ESMO China Voice | Prof. Guiying Xu: High Concordance of PIK3CA Mutations Between Primary and Metastatic Lesions in HR+/HER2– Breast Cancer
  • ESMO China Voice | Prof. Min Yan: First Data from the JS105 Study Announced — Promising Potential in PIK3CA-Mutant Populations
Recent Comments
    Archives
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    Post You Might Like
    Posted inIOncology
    2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care
    Posted by By Peter W. PENG 2025.11.06
    Posted inHematology Frontier
    Professors Michael R. Bishop and Edmund K. Waller Visit Peking University Institute of Hematology:Sino–U.S. Experts Discuss the Future of Cell Therapy
    Posted by By Mourabit Halima 2025.11.06
    Posted inIOncology
    Prof. Kun Wang: A 72-Hour Pegfilgrastim Dosing Strategy Significantly Reduces Bone Pain and Optimizes Supportive Care in Breast Cancer
    Posted by By Mourabit Halima 2025.11.05
    Posted inIOncology
    ESMO China Voice | Prof. Guiying Xu: High Concordance of PIK3CA Mutations Between Primary and Metastatic Lesions in HR+/HER2– Breast Cancer
    Posted by By Peter W. PENG 2025.11.05
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司(香港)
    Scroll to Top

    Welcome to Mediamedic 👋
    It’s nice to meet you.

    Dive into a world of trusted health insights. Subscribe for monthly updates straight to your inbox

    Privacy is part of our care. No spam, just wellness.

    🔒 Privacy policy

    Check your inbox or spam folder to confirm your subscription.

    • Facebook
    • X (Twitter)
    • LinkedIn
    • More Networks
    Share via
    Facebook
    X (Twitter)
    LinkedIn
    Mix
    Email
    Print
    Copy Link
    Copy link
    CopyCopied